JP2023500685A5 - - Google Patents
Info
- Publication number
- JP2023500685A5 JP2023500685A5 JP2022525779A JP2022525779A JP2023500685A5 JP 2023500685 A5 JP2023500685 A5 JP 2023500685A5 JP 2022525779 A JP2022525779 A JP 2022525779A JP 2022525779 A JP2022525779 A JP 2022525779A JP 2023500685 A5 JP2023500685 A5 JP 2023500685A5
- Authority
- JP
- Japan
- Prior art keywords
- alkoxy
- alkyl
- hydrogen
- pharmaceutical product
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930860P | 2019-11-05 | 2019-11-05 | |
| US62/930,860 | 2019-11-05 | ||
| PCT/IB2020/000912 WO2021090061A1 (en) | 2019-11-05 | 2020-11-04 | Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023500685A JP2023500685A (ja) | 2023-01-10 |
| JP2023500685A5 true JP2023500685A5 (cg-RX-API-DMAC10.html) | 2023-11-13 |
| JP7502811B2 JP7502811B2 (ja) | 2024-06-19 |
Family
ID=75849803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525779A Active JP7502811B2 (ja) | 2019-11-05 | 2020-11-04 | Betブロモドメイン阻害物質およびナトリウム依存性グルコース輸送体2阻害物質の組み合わせで主要な心血管有害事象(mace)を処置および/または予防する方法 |
Country Status (18)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12551484B2 (en) | 2019-11-05 | 2026-02-17 | Resverlogix Corp. | Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| EP4236957A4 (en) * | 2020-10-30 | 2024-08-07 | Resverlogix Corp. | METHODS OF LOWERING HBA1C LEVELS USING A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM-DEPENDENT GLUCOSE TRANSPORT-2 INHIBITOR |
| AU2021368618B2 (en) | 2020-10-30 | 2025-02-27 | Resverlogix Corp. | Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| WO2022155303A1 (en) * | 2021-01-14 | 2022-07-21 | Lexicon Pharmaceuticals, Inc. | Sotagliflozin for treating or preventing cardiovascular diseases |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007016525A2 (en) | 2005-07-29 | 2007-02-08 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
| US8114995B2 (en) | 2008-06-26 | 2012-02-14 | Resverlogix Corp. | Methods of preparing quinazolinone derivatives |
| NZ617779A (en) | 2009-03-18 | 2015-08-28 | Resverlogix Corp | Novel anti-inflammatory agents |
| KR20110135411A (ko) | 2009-03-27 | 2011-12-16 | 브리스톨-마이어스 스큅 컴퍼니 | Dpp-iv 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법 |
| US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
| CN106075451A (zh) | 2009-05-27 | 2016-11-09 | 阿斯利康(瑞典)有限公司 | 使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法 |
| PT2773354T (pt) | 2011-11-01 | 2019-07-17 | Resverlogix Corp | Formulações orais de libertação imediata para quinazolinonas substituídas |
| US20130281398A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| PL2986304T3 (pl) | 2013-04-18 | 2022-05-02 | Boehringer Ingelheim International Gmbh | Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania |
| BR112016003584A8 (pt) | 2013-08-21 | 2018-01-30 | Resverlogix Corp | composições farmaceuticas e uso das mesmas para regressão de placa acelerada |
| KR20160043118A (ko) | 2013-08-21 | 2016-04-20 | 리스버로직스 코퍼레이션 | 가속화된 경화반 퇴행을 위한 조성물 및 치료방법 |
| AR099936A1 (es) * | 2014-04-04 | 2016-08-31 | Sanofi Sa | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados |
| CN114984016A (zh) | 2015-03-13 | 2022-09-02 | 雷斯韦洛吉克斯公司 | 用于治疗补体相关疾病之组合物及治疗方法 |
| MA43037A (fr) * | 2015-10-02 | 2018-08-08 | Dana Farber Cancer Inst Inc | Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle |
| JP6849804B2 (ja) | 2016-12-09 | 2021-03-31 | クリスタル ファーマシューティカル(スーチョウ)カンパニー,リミテッド | ブロモドメインタンパク質阻害薬の結晶形及びその製造方法並びに用途 |
| US11419883B2 (en) | 2017-05-05 | 2022-08-23 | The Regents Of The University Of California | Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes |
| US12551484B2 (en) | 2019-11-05 | 2026-02-17 | Resverlogix Corp. | Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| KR20220124736A (ko) | 2020-01-08 | 2022-09-14 | 리스버로직스 코퍼레이션 | Bet 브로모도메인 억제제 및 디펩티딜 펩티다아제 4 억제제의 조합을 이용해 주요 심혈관 이상 반응(mace)을 치료 및/또는 예방하는 방법 |
| AU2021368618B2 (en) | 2020-10-30 | 2025-02-27 | Resverlogix Corp. | Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| EP4236957A4 (en) | 2020-10-30 | 2024-08-07 | Resverlogix Corp. | METHODS OF LOWERING HBA1C LEVELS USING A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM-DEPENDENT GLUCOSE TRANSPORT-2 INHIBITOR |
-
2020
- 2020-11-04 US US17/774,657 patent/US12551484B2/en active Active
- 2020-11-04 FI FIEP20884269.0T patent/FI4054584T3/fi active
- 2020-11-04 EP EP20884269.0A patent/EP4054584B1/en active Active
- 2020-11-04 KR KR1020227019038A patent/KR102935008B1/ko active Active
- 2020-11-04 CA CA3160147A patent/CA3160147A1/en active Pending
- 2020-11-04 AU AU2020377539A patent/AU2020377539B2/en active Active
- 2020-11-04 JP JP2022525779A patent/JP7502811B2/ja active Active
- 2020-11-04 WO PCT/IB2020/000912 patent/WO2021090061A1/en not_active Ceased
- 2020-11-04 ES ES20884269T patent/ES3042146T3/es active Active
- 2020-11-04 CN CN202080076646.1A patent/CN114650824A/zh active Pending
- 2020-11-04 HU HUE20884269A patent/HUE073043T2/hu unknown
- 2020-11-04 BR BR112022008223A patent/BR112022008223A2/pt unknown
- 2020-11-04 DK DK20884269.0T patent/DK4054584T3/da active
- 2020-11-04 TW TW109138504A patent/TWI867086B/zh active
- 2020-11-04 MX MX2022005029A patent/MX2022005029A/es unknown
- 2020-11-04 PT PT208842690T patent/PT4054584T/pt unknown
- 2020-11-04 IL IL292696A patent/IL292696B2/en unknown
- 2020-11-04 PL PL20884269.0T patent/PL4054584T3/pl unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11026900B2 (en) | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative | |
| US6432950B1 (en) | Method for inhibiting neoplastic cells and related conditions by exposure to benzothienopyrimidine derivatives | |
| AU2020234929B2 (en) | Formulations of a compound and uses thereof | |
| US9814724B2 (en) | Antitumor effect potentiator and antitumor agent | |
| RU2005102110A (ru) | Способ и лекарственное средство для лечения тяжелой сердечной недостаточности | |
| IL292696A (en) | Methods for the treatment and/or prevention of severe harmful cardiovascular events with a combination of a bromodomain bet inhibitor and a sodium-dependent glucose transporter 2 inhibitor | |
| CN101107001A (zh) | 配合有α,α,α-三氟胸苷和胸苷磷酸化酶抑制剂的抗癌剂 | |
| JP2023509186A5 (cg-RX-API-DMAC10.html) | ||
| JP2023547475A5 (cg-RX-API-DMAC10.html) | ||
| WO2020045461A1 (ja) | ピラゾロ[3,4-d]ピリミジン化合物を有効成分とする治療剤 | |
| MXPA06014477A (es) | Agente antitumor, fortificador de efecto antitumor y metodo de terapia para cancer. | |
| JP5409613B2 (ja) | 抗腫瘍剤、キット及び癌治療方法 | |
| JP3450399B2 (ja) | 血管新生阻害剤 | |
| JP2023549703A5 (cg-RX-API-DMAC10.html) | ||
| JPS6231689B2 (cg-RX-API-DMAC10.html) | ||
| HK1127546A (en) | Antitumor effect potentiator and antitumor agent | |
| KR20070026443A (ko) | 허혈성 순환기 질환의 예방 및/또는 치료를 위한 약제 |